Treating depression in Parkinson's patients

April 18, 2014

A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's disease (PD).

Published in the journal Psychiatry Research, the study, which assessed cognitive function in depressed and non-depressed patients with PD, found that the dopamine replacement therapy commonly used to treat motor symptoms of Parkinson's disease was associated with a decline in among depressed Parkinson patients.

In contrast, non-depressed Parkinson patients' cognitive function improved on dopamine replacement therapy.

The study also found that mood in depressed Parkinson's patients was actually worse while on dopaminergic medications.

"This was a surprise," said Lee Blonder, Ph.D., the study's principal investigator. "It is the opposite of our original hypothesis that both groups of PD patients would improve in cognitive performance on dopaminergic medications, and that mood in the depressed PD group would also improve."

A cohort of 28 patients with PD—18 nondepressed and 10 depressed—were given a baseline series of tests to assess cognitive function and the incidence and severity of . They were then re-tested with and without their dopamine replacement therapy.

Results revealed a statistically significant interaction between depression and medication status on three measures of verbal memory and a facial affect naming task. In all cases, depressed Parkinson's patients performed significantly more poorly while on dopaminergic medication than while off. The opposite pattern emerged for the non-depressed Parkinson's group.

Depression is a common and serious co-morbidity in patients with Parkinson's; studies suggest that approximately 40 percent of PD patients suffer from depression.

Blonder cautions that these results are to some extent preliminary due to the small cohort of 28 participants. "Additional studies are required before these results should be used to alter treatment plans," Blonder says. But, "future research should ultimately focus on investigating treatment options for patients with Parkinson's and depression to maximize patient function without compromising their mental health."

Explore further: New study links depression in newly diagnosed Parkinson's disease patients to reduced striatal dopamine synthesis

Related Stories

New study links depression in newly diagnosed Parkinson's disease patients to reduced striatal dopamine synthesis

October 10, 2013
According to the Parkinson's Disease Foundation, up to 60% of individuals with Parkinson's disease (PD) exhibit mild to moderate depression, which is often underdiagnosed. It is unclear whether depression results from having ...

Supplements and behavioural therapy make safe headway with Parkinson's

February 11, 2014
In light of the high degree of psychiatric and cognitive symptoms present in Parkinson's disease (PD) sufferers, researchers have reviewed the efficacy of various therapies used to treat depression and anxiety in PD patients.

Higher vitamin D levels associated with better cognition and mood in PD patients

January 16, 2014
A new study exploring vitamin D levels in patients with Parkinson's disease (PD) opens up the possibility of a new avenue of early intervention that may delay or prevent the onset of cognitive impairment and depression. The ...

Researchers identify impaired new learning in persons with Parkinson's disease

March 19, 2014
Kessler Foundation scientists collaborated with colleagues in Spain to study memory and learning in patients with Parkinson Disease (PD). They found that the Parkinson group's ability to learn new information was significantly ...

Depression may increase your risk of Parkinson's disease

October 2, 2013
People who are depressed may have triple the risk of developing Parkinson's disease, according to a study published in the October 2, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

Higher levels of CSF alpha-synuclein predict faster cognitive loss in Parkinson disease

March 11, 2014
The course of Parkinson disease (PD) can vary from gradual deterioration to precipitous decline in motor or cognitive function. Therefore identifying predictors of progression can benefit understanding of PD disease progression ...

Recommended for you

A new insight into Parkinson's disease protein

July 28, 2017
Abnormal clumps of certain proteins in the brain are a prominent feature of Parkinson's and other neurodegenerative diseases, but the role those same proteins might play in the normal brain has been unknown.

Waterlogged brain region helps scientists gauge damage caused by Parkinson's disease

July 26, 2017
Scientists at the University of Florida have discovered a new method of observing the brain changes caused by Parkinson's disease, which destroys neurons important for movement. The development suggests that fluid changes ...

Parkinson's is partly an autoimmune disease, study finds

June 21, 2017
Researchers have found the first direct evidence that autoimmunity—in which the immune system attacks the body's own tissues—plays a role in Parkinson's disease, the neurodegenerative movement disorder. The findings raise ...

Predicting cognitive deficits in people with Parkinson's disease

June 20, 2017
Parkinson's disease (PD) is commonly thought of as a movement disorder, but after years of living with PD approximately twenty five percent of patients also experience deficits in cognition that impair function. A newly developed ...

Pre-clinical study suggests Parkinson's could start in gut endocrine cells

June 15, 2017
Recent research on Parkinson's disease has focused on the gut-brain connection, examining patients' gut bacteria, and even how severing the vagus nerve connecting the stomach and brain might protect some people from the debilitating ...

Hi-res view of protein complex shows how it breaks up protein tangles

June 15, 2017
Misfolded proteins are the culprits behind amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and other neurodegenerative brain disorders. These distorted proteins are unable to perform their normal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.